WallStreetZenWallStreetZen

NASDAQ: IKT
Inhibikase Therapeutics Inc Stock Ownership - Who owns Inhibikase Therapeutics?

Insider buying vs selling

Have Inhibikase Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Roberto BelliniDirector2024-10-211,460,000$1.37
$2.00MBuy
Arvind KushDirector2024-10-21145,000$1.37
$198.65kBuy
Amit MunshiDirector2024-10-21365,000$1.37
$500.05kBuy

1 of 1

IKT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when IKT insiders and whales buy or sell their stock.

IKT Shareholders

What type of owners hold Inhibikase Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Sands Capital Life Sciences Pulse Fund Ii LP146.70%10,950,000$29.02MInsider
Milton H. Werner71.80%5,359,022$14.20MInsider
Roberto Bellini19.56%1,460,000$3.87MInsider
Armistice Capital LLC7.90%589,575$1.56MInstitution
Amit Munshi4.89%365,000$967.25kInsider
Arvind Kush1.94%145,000$384.25kInsider
Blair William Co1.56%116,120$307.72kInstitution
Joseph Frattaroli1.24%92,234$244.42kInsider
Citadel Advisors LLC0.51%37,895$100.42kInstitution
Geode Capital Management LLC0.50%37,330$98.92kInstitution

1 of 2

IKT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
IKT4.35%95.65%Net BuyingNet Buying
CGTX13.23%60.44%Net Buying
MEIP15.83%84.17%Net Buying
CMMB0.93%5.89%
UBX20.48%51.44%Net SellingNet Selling

Inhibikase Therapeutics Stock Ownership FAQ

Who owns Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ: IKT) is owned by 11.21% institutional shareholders, 246.13% Inhibikase Therapeutics insiders, and 0.00% retail investors. Sands Capital Life Sciences Pulse Fund Ii LP is the largest individual Inhibikase Therapeutics shareholder, owning 10.95M shares representing 146.70% of the company. Sands Capital Life Sciences Pulse Fund Ii LP's Inhibikase Therapeutics shares are currently valued at $29.46M.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.